Poster abstracts 55 on important tumour-related aspects of the eukaryotic cell, for example its cell division cycle. In the last decade many of the key regulators of the cell cycle have been identified. The role of the retinoblastoma protein family in regulating the activity of the E2F transcription factors (potent inducers of the G1-S transition of the cell cycle) is now well established. Activation or repression of a series of genes is essential for a smooth passage through each cell cycle phase. Among the target genes of E2F transcription factors are cell-cycle control genes (for example, genes encoding cyclin E and the pocket protein p107, a relative of the retinoblastoma tumour-suppressor gene product pRb) and proteins involved in the actual duplication of the genome (for example DNA pola, TK and CDC6). So far, five E2Fs have been cloned that can bind members of the pocket protein family (pRb, p107 and p130). We set out to identify new target genes of E2Fs by generating monoclonal NIH3T3 cell lines that overexpress a particular E2F species. We used DNA microarrays to screen for fluctuations in mRNA levels of known and unknown genes and found that one major target of E2F1 was insulin-like growth factor-2 (IGF-2). NIH3T3 cells overexpressing E2F1 and growing under low serum conditions show very low levels of IGF-2 expression. A plausible explanation for the frequently observed programmed cell death in E2F1-overexpressing cells after serum withdrawal now becomes apparent. It is known that IGF growth factors can inhibit the apoptotic signals in cells. The fact that IGF-2 levels drop as a consequence of E2F1 overexpression might hamper the resistance of the cells to apoptosis. It might therefore be that overexpression of E2F1 triggers apoptosis and levels of the rescuing IGF-2 are too low to prevent the cells from undergoing apoptosis. During the conference we will present our progress with the new glassbased arrays we currently apply to find more E2F target genes, to study cell cyclerelated phenomena and to identify tumour-specific expression profiles. A complete system containing high density microarrays on glass slides and all necessary experimental reagents has been developed. Utilizing the TSA TM (Tyramide Signal Amplification) technology, the system offers significantly improved sensitivity which reduces sample requirement by 10-50 fold and uses fluorescence-based detection. MICROMAX TM Microarray System I spotted with 2,400 known human genes provides the opportunity to monitor gene expression between two comparative cell lines or tissue samples. In addition to following global changes in gene expression patterns in basic research, the system also offers the potential of detecting changes in gene expression for diagnostic applications. We have used the system to analyze gene expression in human postmortem brains. Samples of parietal cortex of patients with Rett syndrome, an autism-related disease that affects females exclusively, were compared to agematched tissue samples from normal controls. Several genes were up-or down-regulated in the diseased samples. These studies highlight the potential of the MICRO-MAX TM system to measure gene expression in complex biological samples.
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